The influence of vitamin D and vitamin E in the treatment of infertile women with polycystic ovary syndrome

Assessing the effect of adding vitamin D and vitamin E to metformin with dydrogesterone regimen? in the treatment of infertile women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016022821653N5

Enrollment

317

Registered

2016-10-25

Start date

2016-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovary syndrome

Interventions

Intervention 1: intervention group 3: metformin 500mg by Shafa pharmaceuticals? one tablet daily for the first week? two tablets daily for the second week and then three tablets daily from the thir

Treatment - Drugs

intervention group 3: metformin 500mg by Shafa pharmaceuticals? one tablet daily for the first week? two tablets daily for the second week and then three tablets daily from the third week to the re

intervention group 2: metformin 500mg by Shafa pharmaceuticals? one tablet daily for the first week? two tablets daily for the second week and then three tablets daily from the third week to the re

intervention group 1: metformin 500mg by Shafa pharmaceuticals? one tablet daily for the first week? two tablets daily for the second week and then three tablets daily from the third week to the re

intervention group4: metformin 500mg by Shafa pharmaceuticals? one tablet daily for the first week? two tablets daily for the second week and then three tablets daily from the third week to the res

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria? Infertile women with polycystic ovary syndrome (PCOS)? which had no pregnancy history after 12 months of unprotected intercourse. Exclusion criteria? Women with other causes of infertility such as endometriosis? internal and surgical diseases? and patients who do not have polycystic ovary syndrome (PCOS) criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Follicle size. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Endometrial thickness. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Menstural discipline. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Pregnancy. Timepoint: Before intervention and 3 months after intervention. Method of measurement: BHCG.;Weight. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Scale.	—

Measure

Time frame

Follicle size. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Endometrial thickness. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Menstural discipline. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.;Pregnancy. Timepoint: Before intervention and 3 months after intervention. Method of measurement: BHCG.;Weight. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Kavous Solhjo

Jahrom University of Medical Sience

sohjo@jums.ac.ir+98 71 5444 0821

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026